HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mitsubishi Chemical Corp.

Division of Mitsubishi Chemical Holdings Corp.

Latest From Mitsubishi Chemical Corp.

The A-List: 2006's Trend-Shaping Series A Financings

2006's most intriguing Series As reflect VCs' continued emphasis on risk reduction through reprofiling in biotech, and big gains in funding for diagnostics and device start-ups.

BioPharmaceutical Medical Device

Tanabe and Taisho Get Big in Japan

Two of Japan's largest pharmaceutical companies, Tanabe Seiyaku and Taisho Pharmaceutical, are merging in response to hard times in the Japanese pharma industry. Their union, which will take at least a year to complete, will create a combined company with $4.3 billion in sales, ranking it third in Japan in revenues. The move won't solve both companies' weak pipeline problems, but it will increase their total R&D budget and give them more sales clout in the domestic market. And as many Japanese pharma companies struggle for survival, analysts believe more merger activity is inevitable.

BioPharmaceutical Consumer

Rating the Japanese

Long resistant to consolidation, Japan's drug industry is now beginning to hurt too much to ignore the possibility. Yoshio Yano of Japan's International Pharma Consulting, rates the companies in terms of their ability to internationalize--and, for those who can't, their likelihood to become part of another company.

BioPharmaceutical North America

Marketing Whizz

Calypte Biomedical just got approval for a urine-based HIV-1 confirmatory test, showing unbelievers that urine-based assays can be as sensitive--and even more sensitive--than traditional blood-based tests. Since the test's less dangerous for health care workers to handle, the company expects its fortunes to improve dramatically.

Medical Device
See All

Company Information